Rogier C. Buijsman

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index1.7kcitations156works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Microtubule and mitosis dynamics(35), Computational Drug Discovery Methods(34), Melanoma and MAPK Pathways(28), Protein Degradation and Inhibitors(17), Advanced Breast Cancer Therapies(17)

Publications156 total

Abstract 3785: CFON-026 is a macrocycle that disrupts the BTK protein scaffold thereby inhibiting all clinically relevant BTK resistance mutations
Cancer Research·2025
Abstract 5468: A novel kinase degrader antibody conjugate for the treatment of mCRPC
Cancer Research·2025· 1 cited
151 (PB139): CFON-026, a best-in-class macrocyclic non-covalent inhibitor of BTK (WT) and all clinically relevant BTK resistance mutations
European Journal of Cancer·2024
183 (PB171): A novel kinase degrader-based payload for the development of potent Degrader Antibody Conjugates (DACs)
European Journal of Cancer·2024· 1 cited
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination
Frontiers in Oncology·2024· 6 citedOpen Access
Abstract 6044: EPriL: A platform for the rapid identification of degraders of inhibitor-resistant kinases
Cancer Research·2024
Abstract 1960: CFON-026 is a potent non-covalent BTK inhibitor suitable for combination therapy with covalent BTK inhibitors for early eradication of resistance mutations
Cancer Research·2024· 1 cited
Abstract 5814: EPriL macrocycles as a platform for the rapid generation of effective kinase degrader antibody conjugates (DACs)
Cancer Research·2024
Supplementary Table S1 from Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
2023Open Access
Data from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
2023Open Access
Supplementary Table S3 from Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
2023Open Access
Supplementary Table S3 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
2023Open Access
Figure S1 from TTK Inhibitors as a Targeted Therapy for <i>CTNNB1</i> (<b>β</b>-catenin) Mutant Cancers
2023Open Access
Supplementary Table S3 from Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors
2023Open Access
Figure S4 from TTK Inhibitors as a Targeted Therapy for <i>CTNNB1</i> (<b>β</b>-catenin) Mutant Cancers
2023Open Access
Data from TTK Inhibitors as a Targeted Therapy for <i>CTNNB1</i> (<b>β</b>-catenin) Mutant Cancers
2023Open Access
Supplementary Figure S3 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
2023Open Access
Figure S2 from TTK Inhibitors as a Targeted Therapy for <i>CTNNB1</i> (<b>β</b>-catenin) Mutant Cancers
2023Open Access
Supplementary Figure S5 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
2023Open Access
Supplementary Figure S3 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Guido J.R. Zaman(28), Joost C.M. Uitdehaag(24), Jos de Man(21), Nicole Willemsen‐Seegers(15), Martine B.W. Prinsen(13), Antoon M. van Doornmalen(12), Jan Gerard Sterrenburg(9), Jeroen A.D.M. de Roos(8), C. A. A. VAN BOECKEL(6), Yvonne Grobben(6), Jelle Dylus(6), Diep Vu‐Pham(6), Jules P.P. Meijerink(5), Judith R.F. de Vetter(5), Michelle Müller(5), Freek van Cauter(5), Winfried R. Mulder(5), Kirsten Canté-Barrett(4), Rob Pieters(4), J A P Spijkers-Hagelstein(4)